Brokers Issue Forecasts for Alpha Cognition FY2026 Earnings

Alpha Cognition Inc. (NASDAQ:ACOG – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 EPS estimates for Alpha Cognition in a research note issued to investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.20) per share for the year, up from their prior estimate of ($1.27). HC Wainwright currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Alpha Cognition’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Alpha Cognition’s Q4 2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at $0.10 EPS and FY2027 earnings at ($0.29) EPS.

Alpha Cognition (NASDAQ:ACOG – Get Free Report) last posted its earnings results on Wednesday, November 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Alpha Cognition had a negative return on equity of 52.80% and a negative net margin of 147.26%. The firm had revenue of $7.78 million for the quarter, compared to analysts’ expectations of $7.04 million.

ACOG has been the subject of a number of other research reports. Craig Hallum reaffirmed a “buy” rating and issued a $17.00 price target on shares of Alpha Cognition in a report on Friday, August 14th. Raymond James Financial set a $21.00 price objective on Alpha Cognition and gave the company an “outperform” rating in a report on Thursday. Wall Street Zen lowered Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday. Finally, B. Riley Financial began coverage on Alpha Cognition in a research report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Five research analysts have rated the stock with a Buy rating. According to data from MarketBeat, Alpha Cognition presently has an average rating of “Buy” and a consensus price target of $18.20.

View Our Latest Report on Alpha Cognition

Alpha Cognition Price Performance

NASDAQ:ACOG opened at $8.30 on Monday. Alpha Cognition has a 52 week low of $4.50 and a 52 week high of $10.14. The stock’s 50-day moving average price is $8.74 and its 200-day moving average price is $7.28. The stock has a market capitalization of $180.77 million, a PE ratio of -6.06 and a beta of 2.32.

Institutional Trading of Alpha Cognition

Several institutional investors have recently modified their holdings of ACOG. Aristides Capital LLC increased its stake in shares of Alpha Cognition by 1.4% during the first quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock worth $1,200,000 after purchasing an additional 3,052 shares in the last quarter. Pekin Hardy Strauss Inc. acquired a new position in shares of Alpha Cognition during the 3rd quarter worth about $210,000. Marshall Wace LLP acquired a new position in shares of Alpha Cognition during the 3rd quarter worth about $449,000. ACT Capital Partners L.P. acquired a new position in shares of Alpha Cognition during the 3rd quarter worth about $464,000. Finally, Opaleye Management Inc. lifted its stake in Alpha Cognition by 13.0% in the 2nd quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock valued at $20,905,000 after buying an additional 333,517 shares in the last quarter.

Insiders Place Their Bets

In related news, Director Robert Wills acquired 10,000 shares of Alpha Cognition stock in a transaction on Friday, August 21st. The stock was bought at an average cost of $9.62 per share, for a total transaction of $96,200.00. Following the completion of the transaction, the director owned 32,241 shares of the company’s stock, valued at approximately $310,158.42. The trade was a 44.96% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 8.60% of the company’s stock.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.

See Also

Earnings History and Estimates for Alpha Cognition (NASDAQ:ACOG)

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.